Psychotic Disorders - United States

United States

Revenue in the Psychotic Disorders market is projected to reach €2.09bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of -0.10%, resulting in a market volume of €2.08bn by 2029.
In global comparison, most revenue will be generated in the United States (€2,093.00m in 2024).
In relation to total population figures, per person revenues of €0.53k are generated in 2024.

Key regions: Japan, Australia, Europe, India, France

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Psychotic Disorders market in the United States is experiencing significant growth and development due to several key factors.

Customer preferences: Customers in the United States are increasingly seeking effective treatments for psychotic disorders, such as schizophrenia and bipolar disorder. They are looking for medications that not only manage the symptoms but also minimize side effects and improve overall quality of life. There is a growing demand for personalized treatment options that take into account individual patient characteristics and medical history.

Trends in the market: One major trend in the Psychotic Disorders market in the United States is the increasing adoption of atypical antipsychotic medications. These medications have gained popularity due to their improved efficacy and reduced side effects compared to traditional antipsychotics. Healthcare providers are prescribing atypical antipsychotics more frequently, leading to a higher market share for these drugs. This trend is expected to continue as more research is conducted and new atypical antipsychotic medications are developed.Another trend in the market is the rising use of digital health technologies in the treatment of psychotic disorders. Mobile applications, wearable devices, and telemedicine platforms are being utilized to monitor patients, deliver cognitive behavioral therapy, and provide remote consultations. These technologies offer convenience, accessibility, and real-time data collection, improving patient outcomes and reducing healthcare costs. The integration of digital health solutions into the treatment landscape is expected to drive market growth in the coming years.

Local special circumstances: The United States has a well-established healthcare system with a high level of access to healthcare services. This, coupled with a large population and a high prevalence of psychotic disorders, creates a favorable environment for market growth. The presence of leading pharmaceutical companies and research institutions in the country also contributes to the development and availability of innovative treatments for psychotic disorders.

Underlying macroeconomic factors: The United States has a strong economy and high healthcare expenditure, which allows for investment in research and development of new treatments for psychotic disorders. The government and private insurance companies provide coverage for mental health treatments, ensuring affordability and accessibility for patients. Additionally, the increasing awareness and destigmatization of mental health issues in society have led to a greater demand for effective treatments, driving market growth.In conclusion, the Psychotic Disorders market in the United States is experiencing growth and development due to customer preferences for effective and personalized treatments, the adoption of atypical antipsychotic medications, the integration of digital health technologies, the favorable healthcare system and strong economy, and the increasing awareness of mental health issues. These factors are expected to continue driving market growth in the coming years.

Methodology

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.